ADVANCED KRAS G12D MUTANT SOLID TUMORS
Clinical trials for ADVANCED KRAS G12D MUTANT SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new ADVANCED KRAS G12D MUTANT SOLID TUMORS trials appear
Sign up with your email to follow new studies for ADVANCED KRAS G12D MUTANT SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets tough KRAS G12D cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called HRS-4642 combined with several other anti-cancer medicines in 47 adults with advanced solid tumors that have a specific KRAS G12D mutation. The main goals are to check safety, find the best dose, and see if the combination can shrink…
Matched conditions: ADVANCED KRAS G12D MUTANT SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 19:02 UTC
-
New hope for Hard-to-Treat cancers: drug targets KRAS G12D mutation
Disease control OngoingThis early-stage trial tests a new drug called HRS-4642 in 102 adults with advanced solid tumors that have a specific KRAS G12D mutation. The main goals are to check the drug's safety, find the best dose, and see early signs of tumor shrinkage. Participants must have tried other …
Matched conditions: ADVANCED KRAS G12D MUTANT SOLID TUMORS
Phase: PHASE1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:00 UTC